alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```

[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[S. 643 Introduced in Senate (IS)]

112th CONGRESS
  1st Session
                                 S. 643

 To amend title XIX of the Social Security Act to direct Medicaid EHR 
  incentive payments to federally qualified health centers and rural 
                            health clinics.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                             March 17, 2011

Ms. Stabenow (for herself and Ms. Snowe) introduced the following bill; 
     which was read twice and referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
 To amend title XIX of the Social Security Act to direct Medicaid EHR 
  incentive payments to federally qualified health centers and rural 
                            health clinics.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Fix HIT Act of 2011''.

SEC. 2. MEDICAID EHR INCENTIVE PAYMENTS FOR FEDERALLY QUALIFIED HEALTH 
              CENTERS AND RURAL HEALTH CLINICS.

    (a) In General.--Section 1903(t) of the Social Security Act (42 
U.S.C. 1396b(t)) is amended--
            (1) in paragraph (6)(A)(i)--
                    (A) by striking ``are paid'' and inserting ``(I) 
                are paid''; and
                    (B) by inserting before the period at the end the 
                following: ``, and (II) in the case of a provider 
                described in paragraph (2)(A)(iii), are paid directly 
                to the Federally qualified health center or rural 
                health clinic in which the provider predominantly 
                practices, without any deduction or rebate''; and
            (2) by adding at the end the following new paragraph:
            ``(11) Nothing in this subsection shall be construed to 
        allow duplicate payments to a Medicaid provider described in 
        paragraph (2)(A)(iii) and the Federally qualified health center 
        or rural health clinic in which the provider predominantly 
        practices.''.
    (b) Implementation.--Notwithstanding any other provision of law, 
the Secretary of Health and Human Services may implement the amendments 
made by subsection (a) by program instruction or otherwise.
    (c) Effective Date.--The amendments made by subsection (a) shall 
take effect 60 days after the date of enactment of this Act.
                                 <all>
```
Exhibit
32.1





Certification Pursuant to 18
U.S.C. Section 1350, as Adopted Pursuant to


Section 906 of
Sarbanes-Oxley Act of 2002





I, George E. Daddis Jr., the Principal
Executive Officer of WorldGate Communications, Inc., hereby certify, pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that the Form 10-Q of WorldGate
Communications, Inc., for the quarterly period ended June 30, 2009, which this
certification accompanies, fully complies with requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and
information contained in the Form 10-Q for the quarter ended June 30, 2009
fairly presents, in all material respects, the financial condition and results
of operations of WorldGate Communications, Inc.





A signed original of this written
statement required by Section 906 has been provided to WorldGate and will be
retained by WorldGate and furnished to the Securities and Exchange Commission or
its staff upon request.




Dated: 
      August 14, 2009
              
              /s/
      George E. Daddis Jr.George
      E. Daddis Jr.Chief
      Executive Officer(Principal
      Executive Officer)
# Úřední věstník C 134I/2022

| | ISSN 1977-0863 |
| --- | --- |
| Úřední věstník
  Evropské unie | C 134I |
| | |
| České vydání | Informace a oznámení | Ročník 6525. března 2022 |

ISSN 1977-0863

Úřední věstník

Evropské unie

C 134I

České vydání

Informace a oznámení

Ročník 6525. března 2022

---

| Obsah | Strana |
| --- | --- |
| | IV   Informace |
| | INFORMACE ORGÁNŮ, INSTITUCÍ A JINÝCH SUBJEKTŮ EVROPSKÉ UNIE |
| | Evropská komise |
| 2022/C 134 I/01 | Souhrn rozhodnutí Evropské unie o registracích léčivých přípravků ze dne 25. března 2022
  (Zveřejněno podle článku 13 nebo článku 38 nařízení Evropského parlamentu a Rady (ES) č. 726/2004) | 1 |

Obsah

Strana

IV   Informace

INFORMACE ORGÁNŮ, INSTITUCÍ A JINÝCH SUBJEKTŮ EVROPSKÉ UNIE

Evropská komise

2022/C 134 I/01

Souhrn rozhodnutí Evropské unie o registracích léčivých přípravků ze dne 25. března 2022
  (Zveřejněno podle článku 13 nebo článku 38 nařízení Evropského parlamentu a Rady (ES) č. 726/2004)

(Zveřejněno podle článku 13 nebo článku 38 nařízení Evropského parlamentu a Rady (ES) č. 726/2004

1

---

| CS | |
| --- | --- |

CS

---

IV Informace

INFORMACE ORGÁNŮ, INSTITUCÍ A JINÝCH SUBJEKTŮ EVROPSKÉ UNIE

Evropská komise

| 25.3.2022 | CS | Úřední věstník Evropské unie | CI 134/1 |
| --- | --- | --- | --- |

25.3.2022

CS

Úřední věstník Evropské unie

CI 134/1

---

Souhrn rozhodnutí Evropské unie o registracích léčivých přípravků ze dne 25. března 2022

(Zveřejněno podle článku 13 nebo článku 38 nařízení Evropského parlamentu a Rady (ES) č. 726/2004 (1))

(2022/C 134 I/01)

| — | Vydání registrace (článek 13 nařízení Evropského parlamentu a Rady (ES) č. 726/2004): Přijaté













  Datum rozhodnutí | Název léčivého přípravku | INN (mezinárodní nechráněný název) | Držitel rozhodnutí o registraci | Číslo zápisu do rejstříku Společenství | Léková forma | Kód ATC (anatomicko-terapeuticko-chemický kód) | Datum oznámení |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 25.03.2022 | EVUSHELD | tixagevimabum / cilgavimabum | AstraZeneca AB
  151 85 Södertälje, Sverige | EU/1/22/1651 | Injekční roztok | J06BD03 | 25.3.2022 |

—

Vydání registrace (článek 13 nařízení Evropského parlamentu a Rady (ES) č. 726/2004): Přijaté

Datum rozhodnutí

Název léčivého přípravku

INN (mezinárodní nechráněný název)

Držitel rozhodnutí o registraci

Číslo zápisu do rejstříku Společenství

Léková forma

Kód ATC (anatomicko-terapeuticko-chemický kód)

Datum oznámení

25.03.2022

EVUSHELD

tixagevimabum / cilgavimabum

AstraZeneca AB

151 85 Södertälje, Sverige

EU/1/22/1651

Injekční roztok

J06BD03

25.3.2022

Chcete-li se seznámit s veřejnou zprávou o hodnocení dotyčných léčivých přípravků a se souvisejícími rozhodnutími, obraťte se na:

| European Medicines Agency |
| --- |
| Domenico Scarlattilaan 6 |
| 1083 HS Amsterdam |
| NETHERLANDS |

European Medicines Agency

Domenico Scarlattilaan 6

1083 HS Amsterdam

NETHERLANDS

---

(1)  Úř. věst. L 136, 30.4.2004, s. 1.

---
* Pursuant to 5 TH C IR . R. 47.5, the Court has determined that

this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR . R. 47.5.4. United States Court of Appeals

Fifth Circuit 

## FILED March 11, 2005 Charles R. Fulbruge III Clerk IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

_____________________ No. 04-30277

_____________________ ALVIN HARVEY, Plaintiff-Appellant,
versus RICHARD L. STALDER; J. GOODWIN; M. RHODES; MORMAN, Sergeant; WARD, Sergeant; FERGUSON, Sergeant, Defendants-Appellees.

__________________________________________________ Appeal from the United States District Court for the Western District of Louisiana

USDC No. 03-CV-1833

__________________________________________________ Before REAVLEY, JOLLY and PRADO, Circuit Judges. PER CURIAM: * The judgment of the district court is affirmed because the precedent of this circuit requires more than verbal abuse to raise a cause of action under 42 U.S.C. § 1983. Gomez v. Chandler , 163 F.3d 921 (5th Cir. 1999). AFFIRMED.
exv10w4






EXHIBIT 10.4




FIRST AMENDMENT

TO

AGREEMENT OF LIMITED PARTNERSHIP

OF

ENTERPRISE UNIT L.P.




Dated as of December 2, 2009




     This First Amendment (this “Amendment”) to the Agreement of Limited Partnership dated
as of February 20, 2008 (as subsequently amended, the “Partnership Agreement”) of
Enterprise Unit L.P., a Delaware limited partnership (the “Partnership”), is made and
entered into effective as of December 2, 2009, pursuant to the terms of the Partnership Agreement
and in accordance with Section 12.05 thereof.



     Section 1. AMENDMENTS.



          (a) Section 11.01. Paragraph (b) of Section 11.01 of the Partnership Agreement is
hereby amended and restated to read as follows:





     (b) unless otherwise agreed to by the General Partner, the Class A Limited Partner and
a Required Interest, the date that falls on the second trading day immediately following
the first date as of which the distributions with respect to all outstanding EPD Units and
EPE Units held by the Partnership relating to the fourth quarter of fiscal year 2015 have
been paid in full by EPD or EPE, as applicable;



     Section 2. RATIFICATION OF PARTNERSHIP AGREEMENT. Except as expressly modified and amended
herein, all of the terms and conditions of the Partnership Agreement shall remain in full force and
effect.



     Section 3. GOVERNING LAW. THIS AMENDMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE
WITH THE LAWS OF THE STATE OF DELAWARE, EXCLUDING ANY CONFLICTS-OF-LAW RULE OR PRINCIPLE THAT MIGHT
REFER THE GOVERNANCE OR CONTRUCTION OF THIS AGREEMENT TO THE LAWS OF ANOTHER JURISDICTION.



(Signature Page Follows)




 









 





     IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first set
forth above.



	 	 	 	 	 	 	 
	GENERAL PARTNER:	 	EPCO, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ W. Randall Fowler
 

W. Randall Fowler
	 	 
	 

	 	 	 	President and Chief Executive Officer	 	 
	 
	 	 	 	 	 	 
	CLASS A LIMITED PARTNER:	 	EPCO HOLDINGS, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ W. Randall Fowler
 

W. Randall Fowler
	 	 
	 

	 	 	 	President and Chief Executive Officer	 	 
	 
	 	 	 	 	 	 
	CLASS B LIMITED PARTNERS:	 	Representing a majority of Class B Limited
Partners of the Partnership, pursuant to Powers
of Attorney executed in favor of, and granted
and delivered to the General Partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	EPCO, INC.	 	 
	 

	 	 	 	(As attorney-in-fact for the Class B Limited
Partners pursuant to powers of attorney)	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ W. Randall Fowler
 

W. Randall Fowler
	 	 
	 

	 	 	 	President and Chief Executive Officer	 	 






First Amendment to Agreement of Limited Partnership of Enterprise Unit L.P.
# C_2019288EN.01001401.xml

| 26.8.2019 | EN | Official Journal of the European Union | C 288/14 |
| --- | --- | --- | --- |

26.8.2019

EN

Official Journal of the European Union

C 288/14

---

Request for a preliminary ruling from the Corte suprema di cassazione (Italy) lodged on 11 April 2019 — Istituto Nazionale della Previdenza Sociale v VR

(Case C-303/19)

(2019/C 288/18)

Language of the case: Italian

Referring court

Corte suprema di cassazione

Parties to the main proceedings

Appellant: Istituto Nazionale della Previdenza Sociale

Respondent and cross-appellant: VR

Question referred

Should Article 11(1)(d) of Council Directive 2003/109/EC of 25 November 2003 (1) and the principle of equal treatment for long-term residents and national citizens be interpreted to the effect that they preclude national legislation under which, unlike the provisions laid down for nationals of the Member State, the family members of a worker who is a long-term resident and a citizen of a third country are excluded when determining the members of the family unit, for the purpose of calculating the family unit allowance, where those individuals live in the third country of origin?

---

(1)  Council Directive 2003/109/EC of 25 November 2003 concerning the status of third-country nationals who are long-term residents (OJ 2004 L 16, p. 44).

---
<PAGE>

                                                                    EXHIBIT 32.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

     In connection with the Annual Report of Lease Equity Appreciation Fund I,
L.P. (the "Company") on Form 10-K for the fiscal year ended December 31, 2004 as
filed with the Securities and Exchange Commission on the date hereof (the
"Report"), I, Crit S. DeMent, Chief Executive Officer of the Company, certify,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:

     (1) The Report fully complies with the requirements of section 13(a) or
15(d) of the Securities Exchange Act of 1934, and

     (2) The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.

                                                /s/ Crit S. DeMent
                                                --------------------------------
                                                Crit S. DeMent
                                                Chief Executive Officer

                                                March 31, 2005
#### UNITED STATES of America, Plaintiff-Appellee, v. Karl Wilmer FRISON, agent of J.R., a.k.a. Karl Wilmr Frison, Defendant-Appellant.

No. 11-10374

Non-Argument Calendar.

United States Court of Appeals, Eleventh Circuit.

Sept. 23, 2011.

Steven E. Butler, Gloria A. Bedwell, Donna Barrow Dobbins, Maria E. Murphy, Eugene Seidel, Assistant U.S. Attorney, U.S. Attorney’s Office, Mobile, AL, for Plaintiff-Appellee.

Karl Wilmer Frison, Jr., De Funiak Springs, FL, pro se.

*647Before CARNES, BARKETT and MARCUS, Circuit Judges.

PER CURIAM:

Raymond Pierson, appointed counsel for Karl Frison, in this direct criminal appeal, has moved to withdraw from further representation of the appellant and filed a brief pursuant to *Anders v. California,*386 U.S. 738, 87 S.Ct. 1396, 18 L.Ed.2d 493 (1967). Our independent review of the entire record reveals that counsel’s assessment of the relative merit of the appeal is correct. Because independent examination of the entire record reveals no arguable issues of merit, counsel’s motion to withdraw is GRANTED, and Frison’s conviction and sentence are AFFIRMED.
IN THE SUPREME COURT OF PENNSYLVANIA

EASTERN DISTRICT

IN THE INTEREST OF: A.G., A MINOR

PETITION OF: R.M., FATHER :

:

:

:

: No. 337 EAL 2022

Petition for Allowance of Appeal

from the Order of the Superior Court

IN THE INTEREST OF: A.M.G., A MINOR

PETITION OF: R.M., FATHER :

:

:

:

: No. 338 EAL 2022

Petition for Allowance of Appeal

from the Order of the Superior Court

ORDER

PER CURIAM

AND NOW , this 24th day of January, 2023

, the Petition for Allowance of Appeal is

DENIED

.
U.S. flagAn official website of the United States government
                    Here's how you know **Official websites use .gov**
                            
                            A **.gov** website belongs to an official government organization in the United States.
 **Secure .gov websites use HTTPS**
                            
                            A **lock** (                            
                              A locked padlock                                                      
                            
                            ) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.


Menu Agricultural Research Service
						
                    U.S. DEPARTMENT OF AGRICULTURE
 Pasture Systems & Watershed Management Research: University Park, PA
 close



    Research

                    Research Projects
                                    Publications
                                    Collaborations
                                    News
                                    Software
                People

                    Staff Listing
                                    Careers


        


                    Software
                        Integrated Farming Systems Project
                                    Integrated Farm System Model
                                    Dairy Gas Emissions Model
                                    Beef Gas Emissions Model
                                    Projected Future Climate Data for IFSMSearch small
                    Search
            
            ARS Home
                                About ARS
                                Contact Us




ARS Home Northeast Area University Park, Pennsylvania Pasture Systems & Watershed Management Research Docs





- ARS National Programs
- Search for a scientific manuscript
- Search for a research project
- ARS Software
- Programs and Projects
- Collaborations
- Subjects of Investigation
- Publications

Near Real Time Weather Dataheadline bar  These data are from the Long-Term Agro-ecosystem Research Network (LTAR) network Upper Chesapeake Bay site.


Return to top


Connect with ARS Sign up


ARS Home
                            USDA.gov
                            Plain Writing
                            Policies & Links
                            Civil Rights Statements
                            FOIA
                            Accessibility Statement
                            Privacy Policy
                            Non-Discrimination Statement
                            Quality of Information
                            USA.gov
                            WhiteHouse.gov
Exhibit 10.43




ORAL UNDERSTANDING BY AND AMONG THE SPERM BANK OF NEW YORK, INC. AND BIOGENETICS, INC AND THE SPERM AND EMBRYO BANK OF NEW JERSEY, INC.  DATED JANUARY 14, 2005

The Sperm Bank of New York, Inc. in order to carry out its business purpose as an operating reproductive cell/tissue banking service, including sperm, ova, ovarian tissue and testicular tissue requires collection facilities, cryostorage, personnel to interface with donors, bookkeeping and invoicing personnel and other services.

BioGenetics, Inc. and The Sperm and Embryo Bank of New Jersey, Inc. have the facilities and personnel needed by The Sperm Bank of New York, Inc. for its reproductive cell/tissue banking service.

BioGenetics, Inc. and The Sperm and Embryo Bank of New Jersey, Inc. will provide the services required by The Sperm Bank of New York, Inc. as set forth above for $50,000 per year plus reimbursement of  all verified out of pocket expenses

The oral agreement may be cancelled as to the participation by any of the parties on thirty days’ notice to the other parties.
```

[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[S. 718 Introduced in Senate (IS)]

112th CONGRESS
  1st Session
                                 S. 718

  To amend the Federal Insecticide, Fungicide, and Rodenticide Act to 
           improve the use of certain registered pesticides.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                             April 4, 2011

  Mr. Roberts introduced the following bill; which was read twice and 
   referred to the Committee on Agriculture, Nutrition, and Forestry

_______________________________________________________________________

                                 A BILL

 
  To amend the Federal Insecticide, Fungicide, and Rodenticide Act to 
           improve the use of certain registered pesticides.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. USE OF REGISTERED PESTICIDES.

    Section 3(f) of the Federal Insecticide, Fungicide, and Rodenticide 
Act (7 U.S.C. 136a(f)) is amended by adding at the end the following:
            ``(5) Use of registered pesticides.--Notwithstanding any 
        other law, no permit shall be required for--
                    ``(A) the use of a pesticide that is registered or 
                otherwise authorized for use under this Act, if that 
                use is in accordance with this Act; or
                    ``(B)(i) the use of a biological control organism 
                (as defined in section 403 of the Plant Protection Act 
                (7 U.S.C. 7702)) for the prevention, control, or 
                eradication of a plant pest or noxious weed, if that 
                use is in accordance with that Act (7 U.S.C. 7701 et 
                seq.); or
                    ``(ii) the conduct of any other plant pest, noxious 
                weed, or pest control activity under that Act, if that 
                activity is conducted in accordance with that Act.''.
                                 <all>
```
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF AVATEX CORPORATION FOR THE NINE
MONTHS ENDED DECEMBER 31, 1996, AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          MAR-31-1997
<PERIOD-START>                             APR-01-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                          44,489
<SECURITIES>                                    11,319
<RECEIVABLES>                                    5,477
<ALLOWANCES>                                     1,572
<INVENTORY>                                          0
<CURRENT-ASSETS>                                61,226
<PP&E>                                          22,296
<DEPRECIATION>                                   1,319
<TOTAL-ASSETS>                                 185,757
<CURRENT-LIABILITIES>                            9,283
<BONDS>                                         28,012
<PREFERRED-MANDATORY>                          183,370
<PREFERRED>                                          0
<COMMON>                                        69,030
<OTHER-SE>                                   (152,020)
<TOTAL-LIABILITY-AND-EQUITY>                   185,757
<SALES>                                         12,147
<TOTAL-REVENUES>                                12,147
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                   199
<INTEREST-EXPENSE>                               5,162
<INCOME-PRETAX>                                 23,921
<INCOME-TAX>                                    29,596
<INCOME-CONTINUING>                            (5,675)
<DISCONTINUED>                               (256,714)
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (263,731)
<EPS-PRIMARY>                                  (18.01)
<EPS-DILUTED>                                  (18.01)
        

</TABLE>